TACE combined with Sorafenib or Apatinib for treatment of advanced hepatocellular carcinoma / 中国介入影像与治疗学

ABSTRACT

Objective: To comparatively analyze the effect of TACE combined with Sorafenib or Apatinib in treatment of advanced hepatocellular carcinoma (HCC). Methods: Data of 73 patients with advanced HCC were retrospectively analyzed, including 41 underwent TACE combined with Sorafenib (group S) and 32 underwent TACE combined with Apatinib (group A). The therapeutic efficacy, safety and prognosis were compared between 2 groups. Results: No significant difference of object response rate (ORR) nor disease control rate (DCR) was detected between 2 groups after 1, 3, 6 and 12 months' treatment (all P>0.05). Dose adjustment occurred in 20 patients in group A mainly due to the occurrence of hand-foot syndrome, abdominal pain and loss of appetite, and drug discontinued in 9 cases among them. Meanwhile, dose adjustment happened in 6 cases of group S, mainly because of hand-foot syndrome and proteinuria, and no withdrawal occurred in group S. Before dose adjustment, adverse events (AE) in A group was less than in group S (P<0.01). After dose adjustment, no significant difference of AE was found between 2 groups (P=0.20). The progression free survival (PFS) rate of 6, 12 and 18 months was 31.25%(10/32), 6.25%(2/32) and 3.13%(1/32) of group A, respectively, while was 39.02%(16/41), 19.51%(8/41) and 9.76%(4/41) of group S (χ2=5.18, P=0.02). Conclusion: TACE combined with Sorafenib has better effect and safety for treatment of advanced HCC than TACE plus Apatinib.